Regeneron Pharmaceuticals Inc. and Sanofi could face a court order requiring them to withdraw their PCSK9 inhibitor Praluent (alirocumab) from the market in the wake of a jury verdict finding Amgen Inc.'s Repatha (evolocumab) patents are valid.
Praluent Fate Uncertain After Amgen Wins PCSK9 Patent Battle
Sanofi and Regeneron will appeal jury verdict that Amgen patents are valid; judge to consider permanent injunction.